Research Analysts Set Expectations for MDGL FY2028 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Analysts at B. Riley issued their FY2028 EPS estimates for Madrigal Pharmaceuticals in a research report issued to clients and investors on Thursday, May 1st. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings per share of $42.69 for the year. B. Riley has a “Buy” rating and a $460.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share.

Several other research firms have also recently weighed in on MDGL. HC Wainwright lifted their price objective on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JMP Securities reiterated a “market outperform” rating and issued a $443.00 price target on shares of Madrigal Pharmaceuticals in a report on Thursday, April 24th. StockNews.com raised shares of Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. Citigroup boosted their price objective on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group upped their target price on shares of Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $416.33.

Madrigal Pharmaceuticals Stock Down 3.7 %

NASDAQ:MDGL opened at $295.13 on Monday. Madrigal Pharmaceuticals has a 1 year low of $200.08 and a 1 year high of $377.46. The stock has a 50-day moving average price of $323.84 and a two-hundred day moving average price of $315.87. The stock has a market cap of $6.55 billion, a price-to-earnings ratio of -11.77 and a beta of -0.91. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.62) by $0.30. The firm had revenue of $137.25 million during the quarter, compared to analyst estimates of $112.79 million. During the same period last year, the firm earned ($7.38) EPS.

Insider Transactions at Madrigal Pharmaceuticals

In other news, Director James M. Daly sold 15,470 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $347.45, for a total transaction of $5,375,051.50. Following the sale, the director now owns 1,912 shares in the company, valued at $664,324.40. This represents a 89.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Robert E. Waltermire sold 1,227 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $341.07, for a total value of $418,492.89. Following the completion of the sale, the vice president now directly owns 3,728 shares of the company’s stock, valued at approximately $1,271,508.96. The trade was a 24.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,810 shares of company stock worth $10,610,594 in the last three months. Insiders own 22.80% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. VSM Wealth Advisory LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 1st quarter valued at about $25,000. Farther Finance Advisors LLC grew its stake in Madrigal Pharmaceuticals by 825.0% in the 1st quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 99 shares during the last quarter. GAMMA Investing LLC raised its holdings in Madrigal Pharmaceuticals by 131.4% in the 1st quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 67 shares during the period. First Horizon Advisors Inc. lifted its position in Madrigal Pharmaceuticals by 38.9% during the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 44 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter worth approximately $70,000. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.